Insight Molecular Diagnostics (IMDX) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed Intellia Therapeutics (NTLA) over the past year, losing 6.0% versus a loss of 42.7%. Over five years, NTLA leads with a -91.0% price change compared with -94.9% for IMDX. Intellia Therapeutics is the larger company by market cap ($1.71 billion vs $104.4 million), about 16.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | NTLA |
|---|---|---|
| Share price | $3.19 | $12.19 |
| Market cap | $104.39M | $1.71B |
| 1-day change | -7.76% | +4.10% |
| YTD return | -53.87% | +30.26% |
| 1-year return | -5.98% | -42.71% |
| 5-year return | -94.91% | -91.03% |
| EPS (TTM) | $-1.52 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $28.25 |
| 52-week low | $2.42 | $7.95 |
| Distance from 52-week high | -62.51% | -56.85% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +89.58% |
| Average volume | 233.13K | 4.16M |
| Shares outstanding | 32.72M | 140.13M |
| Employees | — | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 16.4 times larger than Insight Molecular Diagnostics by market value ($1.71B vs $104.39M).
- IMDX has outperformed NTLA by 36.7 percentage points over the past year.
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
IMDX vs NTLA FAQ
Which is bigger, Insight Molecular Diagnostics or Intellia Therapeutics?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.71B compared with $104.39M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or NTLA?
IMDX returned -5.98% over the past 12 months, compared with -42.71% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.